1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Liminatus Pharma, Inc. Warrants

Liminatus Pharma, Inc. Warrants

LIMNW
Liminatus Pharma, Inc. WarrantsUS flagNASDAQ Global Select
0.04
USD
-0.01
- -
1.10MMarket Cap
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
Basic EPS, GAAP
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
Book Value per Share
- -
- -
- -
- -
- -
Tangible Book Value per Share
- -
- -
- -
- -
- -
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
- -
- -
- -
Net Income, GAAP
-3
-5
-4
-10
-11
Effective Tax Rate (%)
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
- -
Working Capital
-11
-16
-19
-10
- -
LT Debt
- -
- -
- -
- -
- -
Total Equity
-11
-16
-19
-10
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
1
1
1
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
27
27
45
Market Capitalization
- -
- -
- -

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
1
1
3
Cash, Cash Equivalents & STI
1
- -
2
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
3
10
3
Payables & Accruals
1
9
1
ST Debt
1
1
1
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
-49.25%
Free Cash Flow
- -
- -
587.52%
Net Income, GAAP
- -
- -
187.81%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

APIChatGPT
CEO
Chris Kim
Full Time Employees
1
Sector
Healthcare
Industry
Biotechnology
Address
6 Centerpointe Drive Cerritos CA United States of America 90623
IPO Date
Apr 30, 2025
CIK
0001831874
Website
liminatuspharma.com
Similar Companies
InMed Pharmaceuticals Inc. (INM)
Tourmaline Bio, Inc. (TRML)
Aprea Therapeutics, Inc. (APRE)
Promisia Healthcare Limited (PHL.NZ)
Vaxcell-Bio Therapeutics Co., Ltd. (323990.KQ)
Arvinas, Inc. (ARVN)
Business
Liminatus Pharma, Inc. is a clinical-stage immuno-oncology company that develops novel cancer therapies focused on immune-modulating mechanisms, particularly next-generation CD47-blockade antibodies and related assets; its lead candidate, IBA101, is a humanized anti-CD47 monoclonal antibody designed to promote macrophage-mediated phagocytosis of tumor cells in advanced solid cancers such as non-small cell lung cancer, while avoiding severe anemia and thrombocytopenia associated with first-generation CD47 inhibitors; the pipeline also encompasses chimeric antigen receptor (CAR)-T cell therapies targeting guanylyl cyclase C (GCC) for colorectal, pancreatic, gastric, and esophageal cancers, alongside a GCC cancer vaccine (Ad5.F35-hGCC-Padre) that has advanced to phase II clinical trials. Founded in 2018 and headquartered in La Palma, California, the company operates primarily in the United States with technologies originating from Thomas Jefferson University and South Korea's Innobation Bio. In recent developments, Liminatus completed a business combination with Iris Acquisition Corp in early 2025, enabling its common stock (LIMN) and public warrants (LIMNW) to commence trading on Nasdaq on May 1, 2025; additionally, in October 2025, it signed a memorandum of understanding with Capital Trust Group Limited for up to USD 30 million in equity financing via an earn-out mechanism to advance immunotherapy research and development, alongside plans for further strategic cooperation including potential digital bond financing.